Browsing Tag
Everest Medicines
6 posts
Dimerix (ASX: DXB) buys Phase 2-ready DMX-652 in deal worth up to $292m
Dimerix buys Phase 2-ready DMX-652 for US$5 million upfront, widening its kidney pipeline while taking on milestones, royalties and execution risk ahead.
Dimerix (ASX: DXB) acquires Phase 2-ready DMX-652 as acute kidney injury deal reshapes renal pipeline
Dimerix has acquired a Phase 2-ready acute kidney injury candidate with an open United States clinical application, giving the biotechnology company a nearer-term catalyst beyond its long-running ACTION3 programme.
Everest Medicines gains FDA approval for EVM14 cancer vaccine, boosting mRNA oncology pipeline
Everest Medicines secures FDA approval for EVM14, its first internally developed mRNA cancer vaccine, paving the way for global clinical trials.
Everest Medicines’ EVER001 shows promising Phase 1b/2a trial results for autoimmune kidney disease treatment
Everest Medicines has announced promising preliminary results from its ongoing Phase 1b/2a clinical trial of EVER001, a next-generation…
Everest Medicines launches clinical trial for personalized mRNA cancer vaccine EVM16
Everest Medicines Limited (HKEX: 1952.HK) has announced the launch of an Investigator-Initiated Clinical Trial (IIT) for its innovative…
Everest Medicines commissions mRNA vaccine production plant in Jiashan
Everest Medicines, a China-based biopharmaceutical company, has commenced operations at its mRNA vaccine production plant in Jiashan, Zhejiang…